Uncategorized
Sirolimus can reduce vitreous haze in patients with non-infectious uveitis
A higher proportion of patients with non-infectious uveitis experienced a reduction of their vitreous haze scores to 0 at 5 months after receiving a 440 µg dose of intravitreal sirolimus compared with control subjects receiving a 44 µg dose of sirolimus, according to a study.Two phase 3 studies found 440 µg of intravitreal sirolimus (Santen), a locally delivered mTOR inhibitor, effectively reduced vitreous haze scores to 0, with fewer adverse events, at 5 months’ follow-up for patients with non-infectious uveitis of the posterior segment, Pauline T. Merrill, MD, told Ocular (Read more...)